Navigation Links
Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
Date:3/28/2011

SAN DIEGO, March 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data highlighting the burden of Clostridium difficile infection using National health insurance claims and survey databases will be presented on April 2, 2011 at the 21st Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA).  

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)Poster Presentation Information:Title:

Rates of Recurrence and Mortality among Patients with a Diagnosis of Clostridium Difficile Infection in the United States: An Analysis Using National Health Insurance Claims and Survey DatabasesPresenter:

Erik R. Dubberke, MD, MSPH, Washington University School of Medicine, St. Louis, MODate:

Saturday, April 2, 2011 Time:

1:00 p.m. to 2:15 p.m. Central TimeLocation:

Hilton Anatole Hotel, Trinity Ballroom, Dallas, TexasPresentation #:

152About OptimerOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

ContactsOptimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
2. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
3. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
4. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
5. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
6. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
7. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
8. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
10. Optimer Pharmaceuticals Announces Key Additions to Management Team
11. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Pharmaceutical giant Johnson & Johnson ... woman who says its talc-based powder products caused ovarian ... $5 million in compensatory damages and $50 million ... ) , This is the second ... February, the same court awarded $72 million to the ...
(Date:5/3/2016)... 2016  Forté Elements, LLC (Forté) is excited to announce the launch of its ... nutritional needs of recovery for a variety of clinical conditions. Founded in 2013, Forté ... http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.8 India 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India ... , registered the fastest GDP growth during the first decade of the 21 ... in Brazil and Russia , along ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... director Joe Ferrazano to serve in the newly created position of executive vice ... the agency’s creative efforts in the Chicago and LA offices. He reports to ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... pharmacies, will be represented at the 2016 Asembia Specialty Pharmacy Summit held May ... is the largest U.S. health care conference for the specialty pharmacy industry, with ...
(Date:5/3/2016)... Ind. (PRWEB) , ... May 03, 2016 , ... ... that it has been selected by Tidelands Health, a three hospital system in ... to be constantly on the lookout for technology that enhances communication, drives workflow ...
(Date:5/3/2016)... ... 2016 , ... Nationally recognized personal injury law firm Monge & Associates is honoring ... anyone who wants one for their Mother or any other mother figure. , According to ... Mothers.” Monge goes on to say, “we are choosing to do this by giving ...
(Date:5/3/2016)... ... 03, 2016 , ... Ogawa World USA introduced the first of its kind ... exclusive Smart Application. The Smart 3D combines the best in technological advancement, design, and ... profile and specialized massage program, each user has a tailored experience unparalleled by any ...
Breaking Medicine News(10 mins):